MHLW Alerts About Adverse Effects Of Antidepressants Including GSK’s Paxil
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare May 8 alerted physicians and patients on possible adverse effects of antidepressants. The drugs mentioned by the ministry include Paxil (paroxetine), Luvox/Depromel (fluvoxamine), Toledomin (milnacipran) and Zoloft (sertraline). The Ministry received 268 reports of aggressive behavior after taking the drugs, and actual damage occurred in 35 cases. A casual relation cannot be denied in four cases, according to MHLW. GlaxoSmithKline's Paxil accounts for half of selective serotonin reuptake inhibitors marketed in Japan, and since it was launched in 2000, roughly 1 million patients have taken the drug in Japan. The Japan Society of Mood Disorders has established a committee to raise public attention on the appropriate use of antidepressants. (Click here for more - Japanese language
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.